Last Updated: July 12, 2026

Litigation Details for Cutting Edge Vision, LLC v. T-Mobile US, Inc. (W.D. Tex. 2024)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Cutting Edge Vision, LLC v. T-Mobile US, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation summary and analysis for: Cutting Edge Vision, LLC v. T-Mobile US, Inc. (W.D. Tex. 2024)

Last updated: July 6, 2026

Litigation summary and analysis for Cutting Edge Vision, LLC v. T-Mobile US, Inc. | 6:24-cv-00270

What lawsuit is Cutting Edge Vision, LLC v. T-Mobile US, Inc. (6:24-cv-00270) about?

The case caption indicates a patent dispute brought by Cutting Edge Vision, LLC against T-Mobile US, Inc. in the Northern District of Texas (case number 6:24-cv-00270). The available docket identifier alone does not provide the asserted patents, claim scope, or causes of action (e.g., infringement under 35 U.S.C. § 271, declaratory judgment, or ITC-related claims).

The litigation’s parties and docket number are consistent with a typical US patent infringement filing, but no complaint text, asserted claim tables, or scheduling order content is available in the provided information to support an infringement-content summary.

When was 6:24-cv-00270 filed and what is the procedural posture?

A full procedural posture requires at least one of: the complaint filing date, the assigned judge, the docket entry history (Rule 16 scheduling, motions to dismiss, early claim construction, transfer motions), or the most recent status order. None of those docket specifics are contained in the input, so a case timeline cannot be stated accurately.

What patents are asserted and what claims are at issue?

A litigation summary for a patent case requires:

  • asserted patent publication numbers / patent numbers
  • earliest priority, remaining term, and expiration windows
  • claim chart structure (independent claims asserted, dependent claims, and theory of infringement)
  • accused instrumentalities (networks, devices, features, software services)
  • infringement theories (direct, indirect, inducement, contributory)

Those elements are not included in the provided material, so no accurate patent-by-patent analysis can be produced.

What is Cutting Edge Vision’s infringement theory against T-Mobile?

In patent litigations against a carrier, the typical fact patterns include mobile networking features, advertising/marketing technology, identity/authentication flows, messaging, data connectivity, location, or device management. But without the complaint’s “Accused Products and Services” section and the infringement contentions, any theory attribution would be speculative.

No infringement theory details are available from the docket number alone.

What defenses does T-Mobile US typically raise in cases like this, and what is asserted here?

Standard defenses in US patent cases include:

  • non-infringement of each limitation
  • invalidity (35 U.S.C. §§ 101, 102, 103, 112)
  • unenforceability (inequitable conduct), prosecution laches
  • lack of standing or improper venue
  • patent exhaustion or permission/license (if applicable)

However, a defensibility analysis requires the actual responsive pleadings and any PTAB or IPR filings, none of which are provided.

What is the Markman and claim-construction outlook for 6:24-cv-00270?

Claim construction timing is typically set through a Rule 16 scheduling order with deadlines for:

  • initial disclosures and claim construction proposals
  • opening claim construction brief
  • any expert reports (depending on court track)

No scheduling dates, case management order, or claim construction plan are available here.

What does the case indicate about settlement risk and litigation leverage?

Settlement leverage in patent cases is driven by:

  • how many asserted patents survive any early motion practice
  • strength of non-infringement positions based on accused technology
  • validity challenges viability (especially § 101 and § 103)
  • damages models and the litigation “runway” given time-to-trial

Without the asserted patent set, claim scope, or any motion outcomes, a settlement and leverage assessment cannot be tied to facts.

Are there related PTAB proceedings (IPR/PGR/CBM) tied to the asserted patents?

Patent validity in parallel PTAB proceedings can materially affect case strategy, stay likelihood, and settlement. The docket number alone does not show whether IPRs were filed, instituted, or whether any stay was sought.

No information is provided to list PTAB case numbers, petition grounds, or institution outcomes.

What is the damage posture (reasonable royalty vs. lost profits) if damages are pled?

A damages analysis requires:

  • the asserted royalty theory (book-of-business, comparable licenses, Georgia-Pacific factors)
  • apportionment arguments
  • “date when infringement began” and notice period
  • any offers for license or marking disputes

None of those details are present.

Does 6:24-cv-00270 involve an injunction request?

In patent cases, plaintiffs often request permanent injunctive relief after a potential infringement finding, plus enhanced damages under § 284 and attorneys’ fees under § 285. Whether the complaint includes such relief, and what the post-Tillman or post-eBay standards analysis might be, depends on the specific pleading and the asserted case law.

No complaint relief language is available.

Key timeline table (what is known vs. not shown)

Item Status Source-backed details
Court / docket Known “6:24-cv-00270” and parties “Cutting Edge Vision, LLC” vs “T-Mobile US, Inc.”
Filed date Not provided Not available in the input
Judge / division Not provided Not available in the input
Asserted patents Not provided Not available in the input
Claim scope / infringement theories Not provided Not available in the input
Motion practice / orders Not provided Not available in the input
Trial / Markman dates Not provided Not available in the input
PTAB related cases Not provided Not available in the input

Litigation analysis focused on decision-useful variables

Given only the docket identifier and party names, the only decision-useful analysis that can be stated is structural: the case is a patent dispute in federal court with carrier as defendant, but no factual or legal content can be extracted to support:

  • patent-by-patent invalidity/infringement evaluation
  • assessment of claim strength and enforceability
  • prediction of schedule impacts (stay, transfer, early dispositive motions)
  • damages exposure quantification

No further analysis is warranted without docket-specific filings.

Key Takeaways

  • Cutting Edge Vision, LLC has brought a patent litigation against T-Mobile US, Inc. in federal court under docket 6:24-cv-00270.
  • The provided information does not include asserted patents, claim limitations, infringement theories, or procedural history, so no substantive claim construction, invalidity, infringement, or damages analysis can be produced from the input alone.

FAQs

  1. What court and jurisdiction is associated with Cutting Edge Vision, LLC v. T-Mobile US, Inc. (6:24-cv-00270)?
  2. Which parties are named in 6:24-cv-00270 and what are their roles?
  3. Does 6:24-cv-00270 typically include Markman/claim construction in the schedule?
  4. Are there likely PTAB IPRs or related validity challenges in carrier patent disputes?
  5. What factors most influence settlement timing in patent cases involving mobile carriers?

References

  1. U.S. District Court docket entry identifier as provided in the prompt: Cutting Edge Vision, LLC v. T-Mobile US, Inc., No. 6:24-cv-00270.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.